Serum levels of ACE2 are higher in patients with obesity and diabetes
Abstract Objective As severity of outcome in COVID‐19 is disproportionately higher among individuals with obesity, smokers, patients with hypertension, kidney disease, chronic pulmonary disease, coronary heart disease (CHD), and/or type 2 diabetes (T2D), serum levels of ACE2, the cellular entry poin...
Published in: | Obesity Science & Practice |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Wiley
2020
|
Subjects: | |
Online Access: | http://dx.doi.org/10.1002/osp4.472 https://onlinelibrary.wiley.com/doi/pdf/10.1002/osp4.472 https://onlinelibrary.wiley.com/doi/full-xml/10.1002/osp4.472 |
id |
crwiley:10.1002/osp4.472 |
---|---|
record_format |
openpolar |
spelling |
crwiley:10.1002/osp4.472 2024-09-15T18:32:22+00:00 Serum levels of ACE2 are higher in patients with obesity and diabetes Emilsson, Valur Gudmundsson, Elias F. Aspelund, Thor Jonsson, Brynjolfur G. Gudjonsson, Alexander Launer, Lenore J. Lamb, John R. Gudmundsdottir, Valborg Jennings, Lori L. Gudnason, Vilmundur 2020 http://dx.doi.org/10.1002/osp4.472 https://onlinelibrary.wiley.com/doi/pdf/10.1002/osp4.472 https://onlinelibrary.wiley.com/doi/full-xml/10.1002/osp4.472 en eng Wiley http://creativecommons.org/licenses/by-nc-nd/4.0/ Obesity Science & Practice volume 7, issue 2, page 239-243 ISSN 2055-2238 2055-2238 journal-article 2020 crwiley https://doi.org/10.1002/osp4.472 2024-08-30T04:08:40Z Abstract Objective As severity of outcome in COVID‐19 is disproportionately higher among individuals with obesity, smokers, patients with hypertension, kidney disease, chronic pulmonary disease, coronary heart disease (CHD), and/or type 2 diabetes (T2D), serum levels of ACE2, the cellular entry point for the coronavirus SARS‐CoV‐2, were examined in these high‐risk groups. Methods Associations of ACE2 levels to smokers and patients with hypertension, T2D, obesity, CHD, or COPD were investigated in a single center population‐based study of 5457 Icelanders from the Age, Gene/Environment Susceptibility Reykjavík Study (AGES‐RS) of the elderly (mean age 75 ± 6 years), using multiple linear regression analysis. Results Serum levels of ACE2 were higher in smokers and individuals with T2D and/or obesity while they were unaffected in the other patient groups. Conclusion ACE2 levels are higher in some patient groups with comorbidities linked to COVID‐19 including obesity and T2D and as such may have an emerging role as a circulating biomarker for severity of outcome in the disease. Article in Journal/Newspaper Reykjavík Reykjavík Wiley Online Library Obesity Science & Practice 7 2 239 243 |
institution |
Open Polar |
collection |
Wiley Online Library |
op_collection_id |
crwiley |
language |
English |
description |
Abstract Objective As severity of outcome in COVID‐19 is disproportionately higher among individuals with obesity, smokers, patients with hypertension, kidney disease, chronic pulmonary disease, coronary heart disease (CHD), and/or type 2 diabetes (T2D), serum levels of ACE2, the cellular entry point for the coronavirus SARS‐CoV‐2, were examined in these high‐risk groups. Methods Associations of ACE2 levels to smokers and patients with hypertension, T2D, obesity, CHD, or COPD were investigated in a single center population‐based study of 5457 Icelanders from the Age, Gene/Environment Susceptibility Reykjavík Study (AGES‐RS) of the elderly (mean age 75 ± 6 years), using multiple linear regression analysis. Results Serum levels of ACE2 were higher in smokers and individuals with T2D and/or obesity while they were unaffected in the other patient groups. Conclusion ACE2 levels are higher in some patient groups with comorbidities linked to COVID‐19 including obesity and T2D and as such may have an emerging role as a circulating biomarker for severity of outcome in the disease. |
format |
Article in Journal/Newspaper |
author |
Emilsson, Valur Gudmundsson, Elias F. Aspelund, Thor Jonsson, Brynjolfur G. Gudjonsson, Alexander Launer, Lenore J. Lamb, John R. Gudmundsdottir, Valborg Jennings, Lori L. Gudnason, Vilmundur |
spellingShingle |
Emilsson, Valur Gudmundsson, Elias F. Aspelund, Thor Jonsson, Brynjolfur G. Gudjonsson, Alexander Launer, Lenore J. Lamb, John R. Gudmundsdottir, Valborg Jennings, Lori L. Gudnason, Vilmundur Serum levels of ACE2 are higher in patients with obesity and diabetes |
author_facet |
Emilsson, Valur Gudmundsson, Elias F. Aspelund, Thor Jonsson, Brynjolfur G. Gudjonsson, Alexander Launer, Lenore J. Lamb, John R. Gudmundsdottir, Valborg Jennings, Lori L. Gudnason, Vilmundur |
author_sort |
Emilsson, Valur |
title |
Serum levels of ACE2 are higher in patients with obesity and diabetes |
title_short |
Serum levels of ACE2 are higher in patients with obesity and diabetes |
title_full |
Serum levels of ACE2 are higher in patients with obesity and diabetes |
title_fullStr |
Serum levels of ACE2 are higher in patients with obesity and diabetes |
title_full_unstemmed |
Serum levels of ACE2 are higher in patients with obesity and diabetes |
title_sort |
serum levels of ace2 are higher in patients with obesity and diabetes |
publisher |
Wiley |
publishDate |
2020 |
url |
http://dx.doi.org/10.1002/osp4.472 https://onlinelibrary.wiley.com/doi/pdf/10.1002/osp4.472 https://onlinelibrary.wiley.com/doi/full-xml/10.1002/osp4.472 |
genre |
Reykjavík Reykjavík |
genre_facet |
Reykjavík Reykjavík |
op_source |
Obesity Science & Practice volume 7, issue 2, page 239-243 ISSN 2055-2238 2055-2238 |
op_rights |
http://creativecommons.org/licenses/by-nc-nd/4.0/ |
op_doi |
https://doi.org/10.1002/osp4.472 |
container_title |
Obesity Science & Practice |
container_volume |
7 |
container_issue |
2 |
container_start_page |
239 |
op_container_end_page |
243 |
_version_ |
1810474079132581888 |